FR22C1023I2 - POLYMORPH FORM ST-246 AND PREPARATION PROCESSES - Google Patents

POLYMORPH FORM ST-246 AND PREPARATION PROCESSES

Info

Publication number
FR22C1023I2
FR22C1023I2 FR22C1023C FR22C1023C FR22C1023I2 FR 22C1023 I2 FR22C1023 I2 FR 22C1023I2 FR 22C1023 C FR22C1023 C FR 22C1023C FR 22C1023 C FR22C1023 C FR 22C1023C FR 22C1023 I2 FR22C1023 I2 FR 22C1023I2
Authority
FR
France
Prior art keywords
polymorph form
preparation processes
processes
preparation
polymorph
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR22C1023C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siga Technologies Inc
Original Assignee
Siga Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siga Technologies Inc filed Critical Siga Technologies Inc
Publication of FR22C1023I1 publication Critical patent/FR22C1023I1/en
Application granted granted Critical
Publication of FR22C1023I2 publication Critical patent/FR22C1023I2/en
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/72—4,7-Endo-alkylene-iso-indoles
    • C07D209/76—4,7-Endo-alkylene-iso-indoles with oxygen atoms in positions 1 and 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Inorganic Chemistry (AREA)
FR22C1023C 2010-03-23 2022-06-02 POLYMORPH FORM ST-246 AND PREPARATION PROCESSES Active FR22C1023I2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31674710P 2010-03-23 2010-03-23
US37303110P 2010-08-12 2010-08-12
PCT/US2011/029576 WO2011119698A1 (en) 2010-03-23 2011-03-23 Polymorphic forms st-246 and methods of preparation

Publications (2)

Publication Number Publication Date
FR22C1023I1 FR22C1023I1 (en) 2022-07-22
FR22C1023I2 true FR22C1023I2 (en) 2024-02-16

Family

ID=44656766

Family Applications (1)

Application Number Title Priority Date Filing Date
FR22C1023C Active FR22C1023I2 (en) 2010-03-23 2022-06-02 POLYMORPH FORM ST-246 AND PREPARATION PROCESSES

Country Status (20)

Country Link
US (7) US9339466B2 (en)
EP (1) EP2549871B1 (en)
JP (3) JP6018041B2 (en)
KR (6) KR20150092354A (en)
CN (4) CN103068232B (en)
AP (1) AP3221A (en)
AU (1) AU2011232551B2 (en)
BR (1) BR112012023743B1 (en)
CA (2) CA3030671A1 (en)
CL (1) CL2012002621A1 (en)
DK (1) DK2549871T3 (en)
FR (1) FR22C1023I2 (en)
IL (4) IL221991B (en)
MX (1) MX361428B (en)
NZ (1) NZ602578A (en)
PE (2) PE20130212A1 (en)
RU (2) RU2578606C2 (en)
SG (2) SG10201501936PA (en)
WO (1) WO2011119698A1 (en)
ZA (1) ZA201207141B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8530509B2 (en) 2003-06-20 2013-09-10 Siga Technologies, Inc. Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
EP2549871B1 (en) * 2010-03-23 2018-08-22 Siga Technologies, Inc. Polymorphic form st-246 and methods of preparation
CN111393354B (en) * 2012-08-16 2023-06-20 西佳技术公司 Method for preparing tecovirime
EP3021836B1 (en) 2013-07-19 2020-10-07 Siga Technologies Inc. Amorphous tecovirimat preparation
AU2014353235B2 (en) * 2013-11-19 2019-05-09 Siga Technologies, Inc. Rehydration of micronized tecovirimat monohydrate
MX2017003916A (en) * 2014-09-26 2017-06-30 Millendo Therapeutics Inc Solid drug form of n-(2,6-bis(1-methylethyl)phenyl)-n'-((1-(4-(di methylamino)phenyl)cyclopentyl) methyl)urea hydrochloride and compositions, methods and kits related thereto.
CN108430469A (en) 2016-02-16 2018-08-21 西加技术公司 ST-246 (Te Kaoweirui monohydrates) mixed suspension preparation
JP7145844B2 (en) 2017-03-31 2022-10-03 大阪瓦斯株式会社 ELECTROCHEMICAL DEVICE, ELECTROCHEMICAL MODULE, SOLID OXIDE FUEL CELL, AND MANUFACTURING METHOD
RU2716709C1 (en) * 2019-08-20 2020-03-16 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Oral dosage form of the preparation in capsules for treating and preventing orthopoxvirus-related diseases
TW202320728A (en) * 2021-11-04 2023-06-01 日商興和股份有限公司 Medicinal product
TW202320776A (en) * 2021-11-04 2023-06-01 日商興和股份有限公司 Encapsulated formulation

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670901A1 (en) * 1967-08-09 1971-03-18 Hoechst Ag Process for the preparation of benzenesulfonylureas
US4173646A (en) * 1974-10-04 1979-11-06 Merck & Co., Inc. Tricyclicdicarboximides
US4061763A (en) * 1975-05-09 1977-12-06 Merck & Co., Inc. Tricyclicdicarboximides
US5068356A (en) * 1990-02-20 1991-11-26 Atochem North America, Inc. Hindered phenolic n-(amido)imides
ZA939565B (en) 1993-12-21 1994-08-11 Applied Analytical Ind Inc Method for preparing low dose pharmaceutical products.
MXPA02006660A (en) * 2000-01-07 2002-12-13 Transform Pharmaceuticals Inc Highthroughput formation, identification, and analysis of diverse solidforms.
AU2002222567B2 (en) 2000-12-01 2007-05-10 Kyowa Hakko Kirin Co., Ltd. Composition improved in solubility or oral absorbability
US6596771B2 (en) 2001-01-12 2003-07-22 Schering Corporation Drugs for treating viral infections
US6433016B1 (en) 2001-01-12 2002-08-13 Vassil Stefanov Georgiev Drugs for treating viral infections
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
CA2529761C (en) 2003-06-20 2013-08-13 Siga Technologies, Inc. Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
US8530509B2 (en) 2003-06-20 2013-09-10 Siga Technologies, Inc. Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
US7737168B2 (en) 2003-06-20 2010-06-15 Siga Technologies, Inc. Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
US7687641B2 (en) * 2003-06-20 2010-03-30 Siga Technologies, Inc. Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
US8039504B2 (en) * 2003-06-20 2011-10-18 Siga Technologies, Inc. Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
US20070122471A1 (en) 2003-12-25 2007-05-31 Takeda Pharmaceutical Company Limited Method of improving suitability for granulation
DE602005017194D1 (en) * 2004-12-09 2009-11-26 Zach System Spa PROCESS FOR THE PREPARATION OF CARVEDILOL AND ITS ENANTIOMER
EP1868628B1 (en) * 2005-04-08 2014-06-11 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
US7872037B2 (en) 2006-03-02 2011-01-18 Siga Technologies, Inc. Antiviral drugs for treatment of arenavirus infection
CN101445478B (en) * 2008-08-22 2011-04-06 中国人民解放军军事医学科学院生物工程研究所 Compound ST-246 containing a crystal water, crystal thereof and preparation method thereof
RU2412160C1 (en) * 2009-09-25 2011-02-20 Федеральное государственное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФГУН ГНЦ ВБ "Вектор" Роспотребнадзора) 7-[n'-(4-trifluoromethylbenzolyl)-hydrazinocarbonyl]-tricyclo[3.2.2.02,4]non-8-ene-6-carboxylic acid, having antiviral activity
EP2549871B1 (en) * 2010-03-23 2018-08-22 Siga Technologies, Inc. Polymorphic form st-246 and methods of preparation

Also Published As

Publication number Publication date
IL258239A (en) 2018-05-31
CN105111130A (en) 2015-12-02
US20210137885A1 (en) 2021-05-13
US10406137B2 (en) 2019-09-10
JP6018041B2 (en) 2016-11-02
US20240156782A1 (en) 2024-05-16
US10933050B2 (en) 2021-03-02
CN105175311A (en) 2015-12-23
KR20150011016A (en) 2015-01-29
ZA201207141B (en) 2016-06-29
KR20170102070A (en) 2017-09-06
AP3221A (en) 2015-04-30
CN103068232B (en) 2015-08-26
AU2011232551A1 (en) 2012-10-18
WO2011119698A9 (en) 2013-01-31
CL2012002621A1 (en) 2013-10-11
WO2011119698A1 (en) 2011-09-29
US20160107993A1 (en) 2016-04-21
PE20130212A1 (en) 2013-03-09
JP2016040323A (en) 2016-03-24
KR20130018271A (en) 2013-02-20
PE20170944A1 (en) 2017-07-13
AU2011232551B2 (en) 2014-11-13
KR20160062208A (en) 2016-06-01
US10045964B2 (en) 2018-08-14
EP2549871A4 (en) 2016-03-09
KR20160028489A (en) 2016-03-11
DK2549871T3 (en) 2018-12-10
CA3030671A1 (en) 2011-09-29
RU2015146899A (en) 2019-01-11
JP2013522371A (en) 2013-06-13
CN105111131A (en) 2015-12-02
IL241730A0 (en) 2015-11-30
CA2793533C (en) 2019-02-26
KR20150092354A (en) 2015-08-12
MX361428B (en) 2018-12-06
EP2549871B1 (en) 2018-08-22
CA2793533A1 (en) 2011-09-29
US20190343799A1 (en) 2019-11-14
FR22C1023I1 (en) 2022-07-22
NZ602578A (en) 2014-08-29
US20180311213A1 (en) 2018-11-01
BR112012023743B1 (en) 2020-02-18
RU2012144818A (en) 2014-04-27
IL221991B (en) 2019-06-30
US11890270B2 (en) 2024-02-06
EP2549871A1 (en) 2013-01-30
US20180193308A1 (en) 2018-07-12
IL241731A0 (en) 2015-11-30
US9744154B2 (en) 2017-08-29
SG10201501936PA (en) 2015-05-28
AP2012006514A0 (en) 2012-10-31
SG184201A1 (en) 2012-10-30
CN103068232A (en) 2013-04-24
MX2012010859A (en) 2013-04-29
US9339466B2 (en) 2016-05-17
RU2578606C2 (en) 2016-03-27
BR112012023743A2 (en) 2015-09-15
JP2018012735A (en) 2018-01-25
US20110236434A1 (en) 2011-09-29

Similar Documents

Publication Publication Date Title
FR22C1023I2 (en) POLYMORPH FORM ST-246 AND PREPARATION PROCESSES
SMT201700008B (en) PHARMACEUTICAL COMPOSITION
BR112013013263A2 (en) connection set
BR112013010007A2 (en) catheter apparatus
BR112013011157A2 (en) breathing apparatus
FR3017891B1 (en) STRUCTURES AND METHODS FOR FORMING SLABS
EE201300005A (en) Pharmaceutical composition
BR112013011848A2 (en) improved connection method
BR112012022294A2 (en) articulator
BR112013012506A2 (en) electrolysis apparatus
PL2552910T3 (en) New polymorph
BR112012021749A2 (en) processes and compounds
AT508580A3 (en) TILLAGE EQUIPMENT
DK2642980T3 (en) PEDIATRIC FORMULATION
BR112012029461A2 (en) solifenacin-containing pharmaceutical composition
DK2279652T3 (en) cultivator
DK2425046T3 (en) Blanket
BRPI1014684A2 (en) new isoquinoline derivatives
BR112013015580A2 (en) radiostabilization method
BR112013007492A2 (en) polypropyleterimine glycodendrimers
BR112013000339A2 (en) photocure device
ITMI20112024A1 (en) FLOOR-MADE APPARATUS
BR112012029887A2 (en) pharmaceutical composition
BR112012010525A2 (en) new processes
EP2539157A4 (en) Removable top blanket